Literature DB >> 25381064

T-cell-associated cellular immunotherapy for lung cancer.

Ke Li1, Qing Zhang, Yang Zhang, Jie Yang, Junnian Zheng.   

Abstract

PURPOSE: The aim of the present study was to discuss recent findings on the role of T cells in lung cancer to provide information on their potential application, especially in cellular immunotherapy.
METHODS: Data on the different types of T cells that are currently used for the treatment of lung cancer were obtained by searching the PUBMED database.
RESULTS: Cytotoxic T lymphocytes, natural killer T cells, γδ T cells, lymphokine-activated killer cells, tumor-infiltrating lymphocytes, cytokine-induced killer cells and gene-modified T cells were analyzed to determine the benefits and drawbacks of their application in the treatment of lung cancer. Advances in the study of their antitumor mechanisms and directions for future research were discussed.
CONCLUSIONS: T cells are critical for tumorigenesis and therefore important targets for the treatment of lung cancer. T-cell-associated cellular immunotherapy opens up a window of opportunity for the development of complementary methods to traditional lung cancer treatments, which warrants further investigation to improve the clinical outcomes of lung cancer patients.

Entities:  

Mesh:

Year:  2014        PMID: 25381064     DOI: 10.1007/s00432-014-1867-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  68 in total

1.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

2.  A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.

Authors:  Shinichiro Motohashi; Aki Ishikawa; Eiichi Ishikawa; Mizuto Otsuji; Toshihiko Iizasa; Hideki Hanaoka; Naomi Shimizu; Shigetoshi Horiguchi; Yoshitaka Okamoto; Shin-ichiro Fujii; Masaru Taniguchi; Takehiko Fujisawa; Toshinori Nakayama
Journal:  Clin Cancer Res       Date:  2006-10-06       Impact factor: 12.531

3.  Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL.

Authors:  Stephanie L Goff; Franz O Smith; Jacob A Klapper; Richard Sherry; John R Wunderlich; Seth M Steinberg; Donald White; Steven A Rosenberg; Mark E Dudley; James C Yang
Journal:  J Immunother       Date:  2010-10       Impact factor: 4.456

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 5.  Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer.

Authors:  Qing Zhang; Huizhong Li; Jie Yang; Liantao Li; Baofu Zhang; Jia Li; Junnian Zheng
Journal:  Curr Gene Ther       Date:  2013-02       Impact factor: 4.391

6.  Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.

Authors:  Osamu Kawai; Genichiro Ishii; Kaoru Kubota; Yukinori Murata; Yoichi Naito; Tetsuya Mizuno; Keiju Aokage; Nagahiro Saijo; Yutaka Nishiwaki; Akihiko Gemma; Syoji Kudoh; Atsushi Ochiai
Journal:  Cancer       Date:  2008-09-15       Impact factor: 6.860

Review 7.  Tumor microenvironment: Modulation by decorin and related molecules harboring leucine-rich tandem motifs.

Authors:  Silvia Goldoni; Renato V Iozzo
Journal:  Int J Cancer       Date:  2008-12-01       Impact factor: 7.396

8.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

Authors:  S A Rosenberg; J C Yang; S L Topalian; D J Schwartzentruber; J S Weber; D R Parkinson; C A Seipp; J H Einhorn; D E White
Journal:  JAMA       Date:  1994 Mar 23-30       Impact factor: 56.272

9.  Multiple mechanisms are involved in 6-gingerol-induced cell growth arrest and apoptosis in human colorectal cancer cells.

Authors:  Seong-Ho Lee; Maria Cekanova; Seung Joon Baek
Journal:  Mol Carcinog       Date:  2008-03       Impact factor: 4.784

Review 10.  NKT cells as an ideal anti-tumor immunotherapeutic.

Authors:  Shin-Ichiro Fujii; Kanako Shimizu; Yoshitaka Okamoto; Naoki Kunii; Toshinori Nakayama; Shinichiro Motohashi; Masaru Taniguchi
Journal:  Front Immunol       Date:  2013-12-02       Impact factor: 7.561

View more
  8 in total

Review 1.  Immunotherapy for lung cancer: advances and prospects.

Authors:  Li Yang; Liping Wang; Yi Zhang
Journal:  Am J Clin Exp Immunol       Date:  2016-03-23

2.  Effects of S-1 combined with palliative care on immune function and quality of life of patients with advanced stomach cancer.

Authors:  Ying Wang; Guozhong Li
Journal:  Oncol Lett       Date:  2020-06-09       Impact factor: 2.967

3.  The Effect of ShenQi FuZheng Injection in Combination with Chemotherapy versus Chemotherapy Alone on the Improvement of Efficacy and Immune Function in Patients with Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.

Authors:  Cao Dedong; Xu Huilin; He Anbing; Xu Ximing; Ge Wei
Journal:  PLoS One       Date:  2016-03-25       Impact factor: 3.240

4.  MAP3K3 expression in tumor cells and tumor-infiltrating lymphocytes is correlated with favorable patient survival in lung cancer.

Authors:  Yanli He; Lihui Wang; Weijun Liu; Jinjie Zhong; Shengbin Bai; Zhuwen Wang; Dafydd G Thomas; Jules Lin; Rishindra M Reddy; Nithya Ramnath; Philip W Carrott; William R Lynch; Mark B Orringer; Andrew C Chang; David G Beer; Guoan Chen
Journal:  Sci Rep       Date:  2015-06-19       Impact factor: 4.379

Review 5.  Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis.

Authors:  Erin A Marshall; Kevin W Ng; Sonia H Y Kung; Emma M Conway; Victor D Martinez; Elizabeth C Halvorsen; David A Rowbotham; Emily A Vucic; Adam W Plumb; Daiana D Becker-Santos; Katey S S Enfield; Jennifer Y Kennett; Kevin L Bennewith; William W Lockwood; Stephen Lam; John C English; Ninan Abraham; Wan L Lam
Journal:  Mol Cancer       Date:  2016-10-27       Impact factor: 27.401

6.  The synergistic antitumor effect of arsenic trioxide combined with cytotoxic T cells in pulmonary metastasis model of colon cancer.

Authors:  Lei Wang; Wentao Liang; Na Peng; Xiang Hu; Yingxin Xu; Zhong Liu
Journal:  Oncotarget       Date:  2017-11-30

7.  Effective CpG Delivery Using Zwitterion-Functionalized Dendrimer-Entrapped Gold Nanoparticles to Promote T Cell-Mediated Immunotherapy of Cancer Cells.

Authors:  Huan Chen; Yiming Zhang; Lulu Li; Rui Guo; Xiangyang Shi; Xueyan Cao
Journal:  Biosensors (Basel)       Date:  2022-01-27

Review 8.  Adoptive Immunotherapy in Postoperative Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Authors:  Yuan Zeng; Wenli Ruan; Jiaxi He; Jianrong Zhang; Wenhua Liang; Yaoqi Chen; Qihua He; Jianxing He
Journal:  PLoS One       Date:  2016-09-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.